Suggested remit - To appraise the clinical and cost effectiveness of liraglutide within its marketing authorisation, in addition to diet and physical activity, for the management of people with obesity or overweight with risk factors
 
Status In progress
Process STA 2018
ID number 740

Provisional Schedule

Expected publication 22 July 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Novo Nordisk
Others Department of Social Care
  NHS England
Patient carer groups Helping Overcome Obesity Problems
  Obesity Group of the British Dietetic Association
Professional groups Royal College of Physicians

Commentators

Comparator companies GlaxoSmithKline
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health Northern Ireland
  Health Improvement Scotland
  Welsh Health Specialised Services Committee
  Scottish Medicines Consortium

Timeline

Key events during the development of the guidance:

Date Update
17 February 2020 The second committee discussion of liraglutide for managing overweight and obesity is to be rescheduled. The reschedule will ensure there is sufficient time and technical support to fully consider any new evidence submitted in response to the ACD. This webpage will be updated with the date for discussion of this topic once the next available slot has been identified.
24 January 2020 - 14 February 2020 Appraisal consultation
10 December 2019 Committee meeting: 1
10 April 2019 Invitation to participate
10 April 2019 In progress, In progress
21 September 2018 - 19 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance